After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.
Compare NTLA Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Intellia Therapeutics
It's a good time to be a gene-editing company.
There are still some key unanswered questions for the biotech's promising gene-editing therapy.
After skyrocketing 68% last week, will this stock keep running higher?
The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.
The company is about to fatten its coffers significantly.
New proof-of-concept results are a big deal for the medical community, but what about for your portfolio?
Find out why these stocks are climbing higher.
The company reported promising interim trial results for its CRISPR gene-editing candidate.
Important events on the horizon could push these biotech stocks higher or press them further into the dirt.